Preeclampsia, a disease mainly manifesting as serious hypertension during pregnancy, affects expectant mothers around the globe. Celastrol, a naturally existing triterpenoid, is known to exhibit beneficial effects attenuating cardiovascular symptoms including hypertension. We here assessed the treatment outcome against preeclampsia with a combined use of celastrol and nifedipine. A total of 626 patients with preeclampsia were enrolled, screened, and assigned by random to groups receiving either nifedipine + placebo or nifedipine + celastrol orally. Time required to control hypertension as well as time before another hypertensive crisis were defined as primary end points. Secondary end points include the number of dosages required to control hypertension, as well as maternal and neonatal adverse effects. The time to control hypertension showed a marked reduction in nifedipine + celastrol group, while time before a new hypertensive crisis was significantly lengthened with the treatment, compared with the nifedipine + placebo group. The number of dosages required to control hypertension was also lower in the nifedipine + celastrol group. The two treatment groups were not statistically different regarding adverse effects, either maternal or neonatal. Results from the current study provide evidence for the potential role of celastrol serving as an effective and safe adjuvant to oral nifedipine against hypertension in patients with preeclampsia.

中文翻译：

---

Celastrol与口服硝苯地平协同增效以减轻先兆子痫中的高血压：一项随机，安慰剂对照和双盲试验。

先兆子痫是一种主要表现为怀孕期间严重高血压的疾病，它影响着全球的准妈妈。Celastrol是一种天然存在的三萜类化合物，已知具有减轻心血管症状（包括高血压）的有益作用。我们在这里评估了合并使用Celastrol和硝苯地平对子痫前期的治疗效果。共有626名先兆子痫患者入选，筛查并随机分配至接受硝苯地平+安慰剂或硝苯地平+塞那舒尔口服的组。控制高血压所需的时间以及再次发生高血压危机之前的时间被定义为主要终点。次要终点包括控制高血压所需的剂量数量，以及孕妇和新生儿的不良反应。与硝苯地平+安慰剂组相比，硝苯地平+ celastrol组控制高血压的时间显着减少，而新的高血压危象发生前的治疗时间明显延长。硝苯地平+ celastrol组控制高血压所需的剂量也较少。两个治疗组在孕产妇或新生儿的不良反应方面无统计学差异。本研究的结果提供了证据，表明子痫前期患者中Celastrol作为口服硝苯地平抗高血压的有效和安全佐剂的潜在作用。硝苯地平+ celastrol组控制高血压所需的剂量也较少。两个治疗组在孕产妇或新生儿的不良反应方面无统计学差异。本研究的结果提供了证据，表明子痫前期患者中Celastrol作为口服硝苯地平抗高血压的有效和安全佐剂的潜在作用。硝苯地平+ celastrol组控制高血压所需的剂量也较少。两个治疗组在孕产妇或新生儿的不良反应方面无统计学差异。当前研究的结果提供了证据，表明子痫前期患者Celastrol作为口服硝苯地平抗高血压的有效和安全佐剂的潜在作用。